Bavarian Nordic (BAVA.CO) Interim Report for the Period 1 January to 30 September 2009
11/11/2009 10:40:13 AM
More...
|
Bavarian Nordic (BAVA.CO): New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer
9/22/2009 8:54:36 AM
More...
|
Bavarian Nordic (BAVA.CO) Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
9/15/2009 8:13:01 AM
More...
|
Bavarian Nordic (BAVA.CO) Half Year Interim Report 2009
8/28/2009 10:25:42 AM
More...
|
Bavarian Nordic (BAVA.CO) in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
8/24/2009 8:15:31 AM
More...
|
Bavarian Nordic (BAVA.CO) PROSTVAC(TM) Data Presented at the American Society of Clinical Oncology Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6/2/2009 11:38:56 AM
More...
|
Bavarian Nordic (BAVA.CO): PROSTVAC(TM) Data Presented at the American Society of Clinical Oncology Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6/1/2009 10:00:35 AM
More...
|
The Court Supports Bavarian Nordic (BAVA.CO)'s Decision to Start Patent Infringement Case Against Oxford BioMedica PLC (OXB.L)
5/11/2009 7:35:39 AM
More...
|
Bavarian Nordic (BAVA.CO) Announces its Interim Report for the Period 1 January to 31 March 2009
4/28/2009 8:57:51 AM
More...
|
Bavarian Nordic (BAVA.CO) Publishes its Annual Results 2008
3/27/2009 8:47:07 AM
More...
|
|